Call for Abstracts: DIA EuroMeeting 2017

DIA29 - 31 March 2017, Glasgow, UK.
The DIA EuroMeeting 2017 provides a platform for experts from all relevant disciplines within the entire healthcare development and access process to debate and find solutions to some of the most pertinent challenges faced in an ever-evolving healthcare system - including the need to drive innovation.

DIA invites you to submit presentation, session and tutorial abstracts for the 29th Annual EuroMeeting in Glasgow, UK. You may submit more than one abstract. Abstracts should fall under one of the themes detailed bellow.

Session Abstract
A session abstract is a 90-minute session concept delivered lecture-style from the podium. The abstract author is considered the session chair and will coordinate efforts in recruiting speakers and managing the session (including the facilitation of question and answers from the audience). PowerPoint presentations are required. We encourage innovative ideas for session formats that will enhance interaction between stakeholders.

Presentation Abstract
A presentation abstract is for a 20-minute presentation in a specific topic area; the abstract author is considered the speaker. A PowerPoint presentation is required. If selected, the abstract will consist of a single presentation which will fit within a session.

Tutorial Abstract
A tutorial is a 'hands-on', interactive learning experience. A tutorial consists of 3 hours of instruction with a 30-minute break. The abstract author is considered the instructor. One co-instructor may be recruited but cannot be from the same company/organisation as the author.

Hot-Topic / Stand-Alone Sessions
Each year, there are a number of sessions which do not fit directly under the programme themes. If your abstract clearly does not fit with any of the themes / topics outlined, you may submit it for consideration as a hot-topic / stand-alone presentation or session.

How to maximise the probability of your abstract being accepted
Abstracts will be selected by the EuroMeeting Programme Committee. The theme leaders have indicated the strategic topics they would like to address.

  • Focus your abstracts on the proposed topics in this flyer. If your abstract clearly does not fit, submit it as a hot topic / stand-alone presentation or session
  • Your abstract should be as clear and as detailed as possible to enable the theme leaders to make a judgement on its suitability for the programme
  • Abstracts must be non-promotional and non-commercial in order to be considered

If you have any questions about abstract submission, please email the EuroMeeting team: This email address is being protected from spambots. You need JavaScript enabled to view it.

The deadline for submitting abstracts is Monday, 27 June 2016.

For further information, please visit:
http://www.diaglobal.org/en/conference-listing/meetings/2017/03/29th-annual-euromeeting

About DIA
For over 50 years, DIA has served as a global platform for more than 30,000 health care product development professionals, researchers, regulators, clinicians, academics and patient advocates to collaborate to improve health globally through the advancement of lifesaving medicines and technologies. As the premier professional community for the health care product development ecosystem, DIA (the Drug Information Association) provides global players a neutral and transparent forum for the exchange of ideas and collaboration. By offering access to tools, resources, and networking opportunities, DIA provides its members and international participants objective opportunities for extending debate and discussion to advance scientific and medical innovation.

DIA is an independent, global nonprofit organization based in Washington, DC, USA, with regional offices representing the Americas (Horsham, PA, USA); Europe, the Middle East, and Africa (Basel, Switzerland); and Asia (Beijing, China; Mumbai, India; and, Tokyo, Japan).

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...